Minvera signs co-development deal for Janssen’s insomnia candidate; later opts out of agreement
Minerva Neurosciences Inc. (in-licenses or acquires neurological candidates) signed a preliminary agreement for exclusive rights to develop, manufacture, and market (with right to sublicense) in the EU, Switzerland, Liechtenstein, Iceland, and Norway Janssen Pharmaceutica NV’s Phase I JNJ2847922, a selective orexin-2 antagonist for primary insomnia, and for secondary insomnia as an adjunctive with an antidepressant for the treatment of mood disorders. The compound was renamed MIN202 (seltorexant).
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com